The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients – An EORTC Melanoma Group study

Ophuis, Charlotte M.C. Oude; Verhoef, C.; Rutkowski, Piotr; Powell, Barry; Hage, Jos A. van der; Leeuwen, Paul A. M. van; Voit, Christiane; Testori, Alessandro; Robert, Caroline; Hoekstra, Harald J.; Grünhagen, Dirk J.; Eggermont, Alexander; Akkooi, Alexander C. J. van

doi:10.1016/j.ejso.2016.05.012

Cited by 26 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in keeping with those of Parrett and colleagues 7 and Oude Ophuis and colleagues. 10 Our findings are validated using data from the multinational, prospective MSLT-1 dataset, where delays of less than 30 vs 30 or more days between time of initial diagnosis and definitive surgery had no impact on DFS or MSS in all patients, with and without positive sentinel nodes.…”

Section: Discussionsupporting

confidence: 56%

“…7 Similarly, a series reported by the European Organization for Research and Treatment of Cancer Melanoma Group, which included 1,015 sentinel lymph node-positive patients with a median time of 47 days from diagnosis to definitive surgery, and demonstrated that “delay” time had no impact on 5-year MSS (p = 0.72) and was not an independent prognostic factor for MSS (p = .57). 10 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma

Nelson

Stern

Elashoff

et al. 2017

Journal of the American College of Surgeons

View full text Add to dashboard Cite

BACKGROUND Hypothetically, delay between melanoma diagnosis and SLNB could affect outcomes, either adversely by allowing growth and dissemination of metastases, or beneficially by allowing development of an anti-melanoma immune response. Available data are conflicting about the effect of SLNB delay on patient survival. Our objective was to determine whether delay between initial diagnosis and SLNB affects outcomes in patients with cutaneous melanoma. STUDY DESIGN We performed query and analysis of a large prospectively maintained database of patients with primary cutaneous melanomas undergoing SLNB. An independent dataset from MSLT-1 (Multicenter Selective Lymphadenectomy Trial-1) was used for validation. Primary outcomes included disease-free survival and melanoma-specific survival. RESULTS Early and delayed SLNB were defined as less than 30 and 30 or more days from initial diagnosis, respectively. There were 2,483 patients that met inclusion criteria. Positive sentinel lymph nodes were identified in 17.4% (n = 432). Among all patients, 42% had SLNB 30 or more days after diagnosis and 37% of positive sentinel lymph nodes were at 30 or more days. No differences in sex, anatomic site, or histopathologic features were identified between the 2 groups. There was no difference in melanoma-specific survival or disease-free survival between those undergoing early or delayed SLNB. Examination of MSLT-1 trial data similarly demonstrated no difference in survival outcomes. CONCLUSIONS This, the largest study on this subject to date, found no adverse impact on long-term clinical outcomes of patients due to delay of SLNB beyond 30 days. The MSLT-1 data confirm this result. Patients can be reassured that if the operation is performed 30 or more days after diagnosis, it will not cause harm.

show abstract

Section: Discussionsupporting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma

Nelson

Stern

Elashoff

et al. 2017

Journal of the American College of Surgeons

View full text Add to dashboard Cite

show abstract

“…An update to 2016 was performed in order to include long‐term follow‐up data. Date of diagnosis and date of SNB had been collected previously.…”

Section: Methodsmentioning

confidence: 99%

“…stated that early SNB had a positive effect on the survival of SN‐positive patients. Oude Ophuis and colleagues also investigated this topic, and found no difference in survival in a larger series of 1015 SN‐positive patients; nor did the timing of SNB influence SN positivity in a group of 3546 SN‐positive and ‐negative patients.…”

Section: Introductionmentioning

confidence: 99%

Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma

Ophuis

Akkooi

Rutkowski

et al. 2017

British Journal of Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients with suspected melanoma must have a diagnostic excision within 1 week and be referred to be staged within 3 weeks. However, for early stage patients who have had a radical diagnostic excision, the time taken for a sentinel node procedure is not relevant to prognosis (Nelson et al, 2017;Oude Ophuis et al, 2016). …”

Section: Care Pathways and Timelinesmentioning

confidence: 99%

ECCO essential requirements for quality cancer care for melanoma: Defining how to organise care

Wouters

2018

European Journal of Surgical Oncology

View full text Add to dashboard Cite

The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients – An EORTC Melanoma Group study

Cited by 26 publications

References 28 publications

Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma

Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma

Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma

ECCO essential requirements for quality cancer care for melanoma: Defining how to organise care

Contact Info

Product

Resources

About